At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 156 enrolled
Drug / intervention
LGX818 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating LGX818, Cetuximab, and 1 other intervention for Colorectal Cancer. Completed, enrolled 156 participants across 52 sites in 12 countries.
Detailed Summary
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesAustralia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Norway, South Korea, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartNov 2012
Primary CompletionOct 2015
Study CompletionFeb 2019
TodayJul 2026
First PostedNov 1, 2012
Enrollment StartNov 23, 2012
Primary CompletionOct 31, 2015
Study CompletionFeb 12, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.7 years ago
Interventions
LGX818drug
Cetuximabdrug
BYL719drug